Cardiff Oncology share price logo

Cardiff Oncology

NASDAQ: CRDF

$0.99

+0.05

(+5.70%)

as on

Cardiff Oncology Stock Performance

as on September 1, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.90
    $1.00
    downward going graph

    9.09%

    Downside

    1.01%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.76
    $3.31
    downward going graph

    23.58%

    Downside

    234.34%

    Upside

    downward going graph

Cardiff Oncology share price movements today

Previous Close
$0.94
Open
$0.95
Volume
849.1K
Market Cap
$73.1M
Day's Low - High
$0.90 - $1.00
52 Week Low - High
$0.76 - $3.31

Cardiff Oncology Historical Returns

1 Month Return
+ 9.89 %
3 Month Return
-50.53 %
1 Year Return
-55.24 %
3 Year Return
-48.91 %
5 Year Return
-87.18 %

Cardiff Oncology Stock Fundamentals & Key Indicators

Check Cardiff Oncology market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$73.1M

EPS (TTM)

-0.554

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-41.9M

Revenue (TTM)

508.0K

Profit Margin

0.00%

Return On Equity TTM

-94.09%

Cardiff Oncology vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cardiff Oncology with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$73.1M-87.18%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.2B170.45%31.9286.04%NA
BUY$55.1B-63.37%-7.98-12.57%NA
BUY$85.8B17.94%19.984.86%0.44%

Stock Returns calculator for Cardiff Oncology Stock including INR - Dollar returns

The Cardiff Oncology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cardiff Oncology investment value today

Current value as on today

₹50,860

Returns

-₹49,140

(-49.14%)

Returns from Cardiff Oncology Stock

-₹52,857 (-52.86%)

Dollar Impact

₹3,717 (+3.72%)

Analyst Recommendation on Cardiff Oncology Stock

Based on 6 analysts

BUY

33.33%

Buy

66.67%

Hold

0.00%

Sell

Based on 6 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Cardiff Oncology. Average target price of $5.1

Cardiff Oncology Share Price Target

Get share price movements and forecasts by analysts on Cardiff Oncology.

What analysts predicted

80.59%UPSIDE

Target Price

$5.1

Current Price

$0.99

Analyzed by

6 Analysts

Target

$5.10

Cardiff Oncology target price $5.1, a slight upside of 80.59% compared to current price of $0.99. According to 6 analysts rating.

Indian Investors' Interest in Cardiff Oncology Stock

Search interest for Cardiff Oncology Stock has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-18% versus previous 30 day period

Cardiff Oncology Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
-9
0
0
-11
0
0
0
0
Operating Income
-10
-12
-12
-12
-14
-14
-11
-7
-12
-9
EBITDA
-9
-11
-11
-11
-13
-13
-10
-6
-12
-9
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-10
-11
-11
-11
-13
-13
-11
-7
-12
-9
Income Tax Expense
0
-
-
-
-
-
-
-
-
-
Net Income
-10
-11
-11
-11
-13
-13
-11
-7
-12
-9
Net Profit Margin
-4883.41%
-7225.77%
-7184.85%
-7805.96%
-12324.77%
-11523.14%
-9381.67%
-2969.55%
-30109.76%
-8876.92%

Cardiff Oncology Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
-1
-1
0
0
0
0
0
0
0
0
Operating Income
-40
-25
-17
-16
-19
-28
-39
-45
-48
-48
EBITDA
-36
-22
-15
-15
-18
-27
-38
-41
-45
-44
Interest Expense
1
1
0
0
0
0
1
-
-
-
Depreciation
-
1
0
0
0
0
0
0
0
0
Income Before Tax
-39
-24
-16
-16
-19
-28
-38
-41
-45
-45
Income Tax Expense
0
0
0
0
0
0
-1
0
0
-
Net Income
-39
-24
-16
-16
-19
-28
-38
-41
-45
-45
Net Profit Margin
-10289.76%
-4932.08%
-4354.76%
-6709.74%
-5275.14%
-7880.50%
-10026.94%
-8492.01%
-6651.68%
-7732.04%

Cardiff Oncology Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-11
-11
-11
-13
-13
-11
-7
-12
-9
Operating Cash Flow
-9
-10
-10
-12
-8
-10
-5
-12
-11
Investing Cash Flow
14
-9
4
-14
-4
10
10
3
12
Financing Cash Flow
2
7
44
0
-
0
2
0
0
Change in Cash
6
-12
38
-27
-13
0
7
-8
0

Cardiff Oncology Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-24
-16
-16
-19
-28
-38
-41
-45
-45
Operating Cash Flow
-23
-13
-13
-16
-23
-33
-30
-37
-37
Investing Cash Flow
23
0
0
0
-131
38
36
13
1
Financing Cash Flow
-6
16
12
137
35
0
-
53
2
Change in Cash
-5
3
-1
120
-119
4
5
29
-34

Mutual Funds that own Cardiff Oncology Stock

Check out the Mutual Funds with significant holdings in Cardiff Oncology.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.587351%
2790789
Fidelity Salem Street Trust
0.885036%
688516
Fidelity Concord Street Trust
0.837716%
651704
Franklin Strategic Series
0.564251%
438961
VANGUARD SCOTTSDALE FUNDS
0.465203%
361906

Global Institutional Holdings in Cardiff Oncology

Funds
Holdings
Vanguard
3.64%
iShares
0.29%
Alan Parsow
0.06%
Scott Jarred
0.05%

Insights on Cardiff Oncology

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -12.34M → -9.23M (in $), with an average increase of 33.7% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 41.0K → 104.0K (in $), with an average increase of 60.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 24.7% return, outperforming this stock by 73.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 482.6% return, outperforming this stock by 537.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CRDF stock has moved down by -7.8%

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
OrganisationCardiff Oncology
Headquarters11055 Flintkote Avenue, San Diego, CA, United States, 92121
IndustryBiotechnology
CEODr. Mani Mohindru Ph.D.
E-voting on sharesClick here to vote

Key Management of Cardiff Oncology

Name

Title

Ms. Brigitte Lindsay

Chief Accounting Officer

Dr. Tod Smeal Ph.D.

Chief Scientific Officer

Ms. Elizabeth Anderson

VP of Finance & Administration

Dr. Mani Mohindru Ph.D.

President, CEO & Director

Dr. Roger Sidhu FRCPC, M.D.

Chief Medical Officer

Mr. Josh Muntner BFA, M.B.A.

Chief Financial Officer

Dr. Ajay Aggarwal M.B.A., M.D.

Chief Operating Officer

FAQs

What is Cardiff Oncology share price today?

Cardiff Oncology share price today is $0.99 as on at the close of the market. Cardiff Oncology share today touched a day high of $1.00 and a low of $0.90.

What is the 52 week high and 52 week low for Cardiff Oncology share?

Cardiff Oncology share touched a 52 week high of $3.31 on and a 52 week low of $0.76 on . Cardiff Oncology stock price today i.e. is closed at $0.99,which is 70.09% down from its 52 week high and 30.85% up from its 52 week low.

What is Cardiff Oncology's market capitalisation today?

Cardiff Oncology market capitalisation is $0.00T as on .

How to invest in Cardiff Oncology Stock (CRDF) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cardiff Oncology on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cardiff Oncology Shares that will get you 1.5152 shares as per Cardiff Oncology share price of $0.99 per share as on September 1, 2026 at 8:45 am IST.

What is the minimum amount required to buy Cardiff Oncology Stock (CRDF) from India?

Indian investors can start investing in Cardiff Oncology (CRDF) shares with as little as ₹94.94 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Cardiff Oncology stock (as per the Rupee-Dollar exchange rate as on ). Based on Cardiff Oncology share’s latest price of $0.99 as on September 1, 2026 at 8:45 am IST, you will get 10.1010 shares of Cardiff Oncology. Learn more about fractional shares .

What are the returns that Cardiff Oncology has given to Indian investors in the last 5 years?

Cardiff Oncology stock has given -87.18% share price returns and 30.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?